Considering the early safety data from clinical trials [29,30], our study identifies the IRAK4 inhibitor emavusertib as a novel compound to be explored as single agent in trials for patients with MYD88-mutated indolent B cell lymphomas and as combination partner with BTK or PI3K inhibitors in unselected populations of patients. The gene discussed is IRAK4; the disease is B-cell non-Hodgkin lymphoma.